1248.1000 3.40 (0.27%)
NSE Oct 03, 2025 15:31 PM

1248.10
0.27%
Emkay
Adjusted for the milestone payment received from Journey Medical Corp, 3QFY25 EBITDA for Dr Reddy’s was below street/our estimates. The PAT miss was higher on account of lower other income.
Dr. Reddy's Laboratories Ltd. average weekly volume is high.
More from Dr. Reddy's Laboratories Ltd.
Recommended